Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Dec;66(4):1174-84.
doi: 10.1111/j.1541-0420.2010.01402.x.

Testing a primary and a secondary endpoint in a group sequential design

Affiliations

Testing a primary and a secondary endpoint in a group sequential design

Ajit C Tamhane et al. Biometrics. 2010 Dec.

Abstract

We consider a clinical trial with a primary and a secondary endpoint where the secondary endpoint is tested only if the primary endpoint is significant. The trial uses a group sequential procedure with two stages. The familywise error rate (FWER) of falsely concluding significance on either endpoint is to be controlled at a nominal level α. The type I error rate for the primary endpoint is controlled by choosing any α-level stopping boundary, e.g., the standard O'Brien-Fleming or the Pocock boundary. Given any particular α-level boundary for the primary endpoint, we study the problem of determining the boundary for the secondary endpoint to control the FWER. We study this FWER analytically and numerically and find that it is maximized when the correlation coefficient ρ between the two endpoints equals 1. For the four combinations consisting of O'Brien-Fleming and Pocock boundaries for the primary and secondary endpoints, the critical constants required to control the FWER are computed for different values of ρ. An ad hoc boundary is proposed for the secondary endpoint to address a practical concern that may be at issue in some applications. Numerical studies indicate that the O'Brien-Fleming boundary for the primary endpoint and the Pocock boundary for the secondary endpoint generally gives the best primary as well as secondary power performance. The Pocock boundary may be replaced by the ad hoc boundary for the secondary endpoint with a very little loss of secondary power if the practical concern is at issue. A clinical trial example is given to illustrate the methods.

PubMed Disclaimer

Figures

Figure 1
Figure 1
FWER as a function of ρ and Δ1 when (c1,c2)=(1.6782,1.678), n1 = n2 and d1 = d2 = z.05 = 1.645
Figure 2
Figure 2
FWER as a function of ρ and Δ1 when (c1,c2)=(1.6782,1.678), n1 = n2 and d1 = d2 = z.0303 = 1.876
Figure 3
Figure 3
FWER as a function of ρ and Δ1 when (c1,c2)=(d1,d2)=(1.6782,1.678) and n1 = n2
Figure 4
Figure 4
Secondary powers of the six boundary combinations (OF = O’Brien-Fleming, PO = Pocock, AH = Ad-Hoc, 1 = Primary, 2 = Secondary) for the primary and secondary endpoints as functions of Δ1 for ρ = 0.4 and Δ2 = 1 when α = 0.05 and n1 = n2
Figure 5
Figure 5
Secondary powers of the six boundary combinations (OF = O’Brien-Fleming, PO = Pocock, AH = Ad-Hoc, 1 = Primary, 2 = Secondary) for the primary and secondary endpoints as functions of Δ1 for ρ = 0.4 and Δ2 = 2 when α = 0.05 and n1 = n2
Figure 6
Figure 6
Secondary powers of the six boundary combinations (OF = O’Brien-Fleming, PO = Pocock, AH = Ad-Hoc, 1 = Primary, 2 = Secondary) for the primary and secondary endpoints as functions of Δ1 for ρ = 0.4 and Δ2 = 3 when α = 0.05 and n1 = n2

References

    1. Berger RL, Boos DD. P-value maximized over a confidence set for the nuisance parameter. Journal of the American Statistical Association. 1994;89:1012–1016.
    1. Dmitrienko A, Offen WW, Westfall PH. Gatekeeping strategies for clinical trials that do not require all primary effects to be significant. Statistics in Medicine. 2003;22:2387–2400. - PubMed
    1. Dmitrienko A, Tamhane AC. Gatekeeping procedures with clinical trial applications. Journal of Pharmaceutical Statistics. 2007;6:171–180. - PubMed
    1. Dmitrienko A, Tamhane AC. Gatekeeping procedures in clinical trials. In: Dmitrienko A, Tamhane AC, Bretz F, editors. Multiple Testing Problems in Pharmaceutical Statistics. Chapter 5. Boca Raton, FL: Taylor & Francis; 2009.
    1. Glimm E, Maurer W, Bretz F. Hierarchical testing of multiple endpoints in group-sequential trials. Statistics in Medicine, to appear 2009 - PubMed

Publication types

LinkOut - more resources